Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Numerical simulation and design recommendations for prestressed steel stayed columns subjected to static and dynamic effects.

Scientific reports·2025
Same author

Neostigmine-induced weakness after sugammadex - a reply.

Anaesthesia·2019
Same author

Neostigmine-induced weakness: what are the facts?

Anaesthesia·2018
Same author

Neostigmine as an antagonist of residual block: best practices do not guarantee predictable results.

British journal of anaesthesia·2018
Same author

Sugammadex-induced bradycardia and asystole: how great is the risk?

British journal of anaesthesia·2018
Same author

Conceptual and technical insights into the basis of neuromuscular monitoring.

Anaesthesia·2017
Same journal

Audit of procedural sedation complications using a novel digital application.

British journal of anaesthesia·2026
Same journal

Social deprivation and morbidity and mortality after surgery. Comment on Br J Anaesth 2025; 135: 1193-1202.

British journal of anaesthesia·2026
Same journal

Single-dose intraoperative methadone and QTc interval: a prospective observational cohort investigation.

British journal of anaesthesia·2026
Same journal

Postoperative outcomes in older patients with postoperative delirium in the UK: timing of postoperative delirium screening in the SNAP-3 study. Comment on Br J Anaesth 2026; 136: 1578-87.

British journal of anaesthesia·2026
Same journal

Population pharmacokinetic-pharmacodynamic analysis and dose optimisation of ciprofol in paediatric anaesthesia.

British journal of anaesthesia·2026
Same journal

Global environmental and geo-economic impact of conservative versus liberal oxygen strategies in mechanically ventilated critically ill adults: an ecological country-level analysis.

British journal of anaesthesia·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Neuromuscular dose-response studies: determining sample size.

A F Kopman1, C A Lien, M Naguib

  • 1Department of Anesthesiology, Weill Cornell Medical College, 525 East 68th Street, New York City, NY 10065, USA. akopman@nyc.rr.com

British Journal of Anaesthesia
|November 12, 2010
PubMed
Summary
This summary is machine-generated.

A minimum sample size of 24 subjects is recommended for dose-response studies of neuromuscular blockers. This ensures adequate power for determining clinical potency, addressing a common requirement for Institutional Review Boards and journals.

More Related Videos

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability
09:11

Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability

Published on: February 23, 2016

Related Experiment Videos

Last Updated: Jun 6, 2026

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Measuring Neuromuscular Junction Functionality
10:40

Measuring Neuromuscular Junction Functionality

Published on: August 6, 2017

Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability
09:11

Performing Permanent Distal Middle Cerebral with Common Carotid Artery Occlusion in Aged Rats to Study Cortical Ischemia with Sustained Disability

Published on: February 23, 2016

Area of Science:

  • Pharmacology
  • Clinical Research Methodology
  • Biostatistics

Background:

  • Dose-response studies for neuromuscular blockers often lack a priori power analysis for sample size determination.
  • Institutional Review Boards and journals increasingly require sample size justification.
  • This study proposes a method to determine adequate sample sizes for such studies.

Purpose of the Study:

  • To outline a method for determining the minimal sample size for dose-response studies of neuromuscular blockers.
  • To provide guidance for investigators and meet regulatory/journal requirements.
  • To establish a reliable sample size for assessing drug potency.

Main Methods:

  • Determined dose-response slopes for eight neuromuscular blocking agents using regression analysis.
  • Calculated the coefficient of variation (COV) for the ED₅₀ of each drug using the Hill equation.
  • Performed a priori one-sample t-tests to determine sample size based on allowable error in ED₅₀ (±10-20%).

Main Results:

  • The average COV for ED₅₀ was 22% (range 15-27%).
  • A sample size of 24 subjects provides 80% power with a ±15% allowable error in the mean ED₅₀.
  • Achieving higher accuracy (e.g., ±12% error) requires larger sample sizes (n=37).

Conclusions:

  • A retrospective analysis suggests a minimum sample size of 24 subjects is sufficient.
  • This sample size provides reasonable assurance for determining the clinical potency of neuromuscular blocking drugs.
  • The proposed method aids in planning robust dose-response studies.